These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29891209)

  • 1. Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.
    López-Estebaranz JL; de la Cueva-Dobao P; de la Torre Fraga C; Galán Gutiérrez M; González Guerra E; Mollet Sánchez J; Belinchón Romero I
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):631-642. PubMed ID: 29891209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert report on psoriasis: Spanish dermatologists' opinions on the use of biologic agents to manage moderate to severe psoriasis in adults.
    Puig L; de la Cueva P; Linares M; Suarez J; Velasco M; Vidal D; Zulaica A; García-Calvo C
    Actas Dermosifiliogr; 2013 Jun; 104(5):400-8. PubMed ID: 23669590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
    Puig L; Carrascosa JM; Carretero G; de la Cueva P; Lafuente-Urrez RF; Belinchón I; Sánchez-Regaña M; García-Bustínduy M; Ribera M; Alsina M; Ferrándiz C; Fonseca E; García-Patos V; Herrera E; López-Estebaranz JL; Marrón SE; Moreno JC; Notario J; Rivera R; Rodriguez-Cerdeira C; Romero A; Ruiz-Villaverde R; Taberner R; Vidal D;
    Actas Dermosifiliogr; 2013 Oct; 104(8):694-709. PubMed ID: 24018211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Warren RB; Lunt M; Mason KJ; Evans I; McElhone K; Smith CH; Reynolds NJ; Ashcroft DM; Griffiths CEM;
    J Invest Dermatol; 2018 Apr; 138(4):775-784. PubMed ID: 29080680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to the Epidemiology, Disease Management, and Current Challenges in the Management of Generalized Pustular Psoriasis Through a Survey Conducted Among Spanish Dermatologists.
    Vilarrasa E; Rivera R; Eiris N; Carretero G; de la Cueva P; Carrascosa JM
    Actas Dermosifiliogr; 2024 May; 115(5):449-457. PubMed ID: 37925068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
    Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
    J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
    Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
    Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
    Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
    J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
    [No Abstract]   [Full Text] [Related]  

  • 12. Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey.
    Gooderham M; Papp K; Albrecht L; Grewal P; Gaudreau AJ
    J Drugs Dermatol; 2021 Feb; 20(2):126-132. PubMed ID: 33538558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.
    Al Hammadi A; Al-Sheikh A; Ammoury A; Ghosn S; Gisondi P; Hamadah I; Kibbi AG; Shirazy K
    J Dermatolog Treat; 2017 Mar; 28(2):129-135. PubMed ID: 27196814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital.
    Sanz-Gil R; Pellicer A; Montesinos MC; Valcuende-Cavero F
    J Dermatolog Treat; 2020 Jun; 31(4):370-377. PubMed ID: 30924390
    [No Abstract]   [Full Text] [Related]  

  • 15. [Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis].
    Ara M; Pérez A; Ferrando J
    Actas Dermosifiliogr; 2011 Nov; 102(9):706-16. PubMed ID: 21600532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.
    Carretero Hernández G; Ferrándiz C; Rivera Díaz R; Daudén Tello E; de la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Belinchón Romero I; López-Estebaranz JL; Alsina Gibert M; Sánchez-Carazo JL; Ferrán Farrés M; González Quesada A; Carrascosa Carrillo JM; Llamas-Velasco M; Mendiola Fernández MV; Ruiz Genao D; Muñoz Santos C; García-Doval I; Descalzo MA;
    Actas Dermosifiliogr (Engl Ed); 2018 Sep; 109(7):617-623. PubMed ID: 29887167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
    Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
    Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of childhood psoriasis in France. A national survey among general practitioners, pediatricians, and dermatologists.
    Mahé E; Bursztejn AC; Phan A; Corgibet F; Beauchet A
    Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29193624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of use of biologics in psoriasis among Indian dermatologists - A cross sectional survey.
    Neema S; Dabbas D; Radhakrishnan S; Yadav AK
    Indian J Dermatol Venereol Leprol; 2022; 88(4):515-518. PubMed ID: 33666030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Adherence to Biologic Agents in Psoriasis.
    Hsu DY; Gniadecki R
    Dermatology; 2016; 232(3):326-33. PubMed ID: 27093295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.